e-learning
resources
ERJ
2010
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Identification of a novel water-soluble activator of wild-type and F508del CFTR: GPact-11a
Bertrand J., Boucherle B., Billet A., Melin-Heschel P., Dannhoffer L., Vandebrouck C., Jayle C., Routaboul C., Molina M-C., Décout J-L., Becq F., Norez C.
Source:
Eur Respir J 2010; 36: 311
Journal Issue:
August
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Bertrand J., Boucherle B., Billet A., Melin-Heschel P., Dannhoffer L., Vandebrouck C., Jayle C., Routaboul C., Molina M-C., Décout J-L., Becq F., Norez C.. Identification of a novel water-soluble activator of wild-type and F508del CFTR: GPact-11a. Eur Respir J 2010; 36: 311
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cystic fibrosis and intestinal organoids
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Novel therapeutics for cystic fibrosis
Related content which might interest you:
Improved CFTR and lung function with VX-770, a novel investigational potentiator of CFTR, in subjects with the G551D-CFTR mutation
Source: Annual Congress 2010 - Cystic fibrosis: new targets for therapy and impact of viral infections
Year: 2010
Rescue of mutant ABCA3 by small molecular correctors
Source: International Congress 2017 – Lung fibrosis: basic science
Year: 2017
Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis
Source: Eur Respir Rev 2013; 22: 58-65
Year: 2013
Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two
F508del
alleles
Source: ERJ Open Res, 5 (2) 00082-2019; 10.1183/23120541.00082-2019
Year: 2019
Evaluation of
MRP1-5
gene expression in cystic fibrosis patients homozygous for the ΔF508 mutation
Source: Annual Congress 2003 - Cystic fibrosis: new genes, new controversies
Year: 2003
Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation
Source: Eur Respir Rev 2013; 22: 66-71
Year: 2013
Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient
Source: Eur Respir J 2002; 19: 374-376
Year: 2002
Novel insights into surfactant protein C trafficking revealed through the study of a pathogenic mutant
Source: Eur Respir J, 59 (1) 2100267; 10.1183/13993003.00267-2021
Year: 2022
A novel
CFTR
mutation found in a Chinese cystic fibrosis patient
Source: Eur Respir J 2005; 26: Suppl. 49, 402s
Year: 2005
Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator
Source: Eur Respir J, 57 (6) 2002774; 10.1183/13993003.02774-2020
Year: 2021
Analysis of CFTR gene mutations in 24 Japanese individuals with cystic fibrosis
Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more
Year: 2010
ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies
Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020
Year: 2020
Rescue of CFTR function impaired by mutations in exon 15
Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis
Year: 2020
Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis
Source: Eur Respir J 2011; 37: 59-69
Year: 2011
Genotypic diversity of
Pseudomonas aeruginosa
in cystic fibrosis patients with the CFTR I1234V mutation in a large kindred family
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems
Year: 2012
A three miRNA signature regulates the CF transmembrane conductance regulator (CFTR) in cystic fibrosis airway epithelium
Source: Annual Congress 2011 - Epithelial cells: role in health and disease
Year: 2011
Analysis of CFTR function in human monocytes
Source: Annual Congress 2010 - Cystic fibrosis: lung disease and much more
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept